Jefferies Financial Group Inc. (JEF) is a publicly traded Financial Services sector company. As of July 5, 2026, JEF trades at $52.62 with a market cap of $10.70B and a P/E ratio of 17.96. JEF moved +2.57% today. Year to date, JEF is -16.12%; over the trailing twelve months it is -7.06%. Its 52-week range spans $35.53 to $82.68. Analyst consensus is buy with an average price target of $63.40. Rallies surfaces JEF's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Jefferies Upgrades Abivax to Buy, Raises Price Target on Obefazimod Safety: Jefferies has upgraded Abivax shares to Buy from Neutral and raised its price target after safety concerns around its lead drug obefazimod eased. The move reflects Jefferies’ confidence in improved clinical tolerability following recent trial data that showed fewer adverse liver events.
| Metric | Value |
|---|---|
| Price | $52.62 |
| Market Cap | $10.70B |
| P/E Ratio | 17.96 |
| EPS | $2.93 |
| Dividend Yield | 0.40% |
| 52-Week High | $82.68 |
| 52-Week Low | $35.53 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $10.82B |
| Net Income | $682.04M |
| Gross Margin | 98.24% |
5 analysts cover JEF: 0 strong buy, 2 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $63.40.